Sara S, Tv D, Dg G, Elumalai B, Javid M
Cureus. 2024; 16(1):e52839.
PMID: 38406120
PMC: 10884782.
DOI: 10.7759/cureus.52839.
Zhou W, Zhao P, Gao J, Zhang Y
BMC Pediatr. 2023; 23(1):500.
PMID: 37784084
PMC: 10544472.
DOI: 10.1186/s12887-023-04326-1.
Nicole S, Lory P
Front Pharmacol. 2021; 12:751095.
PMID: 34671263
PMC: 8521073.
DOI: 10.3389/fphar.2021.751095.
Desaphy J, Altamura C, Vicart S, Fontaine B
J Neuromuscul Dis. 2020; 8(3):357-381.
PMID: 33325393
PMC: 8203248.
DOI: 10.3233/JND-200582.
Kokunai Y, Dalle C, Vicart S, Sternberg D, Pouliot V, Bendahhou S
Sci Rep. 2018; 8(1):16681.
PMID: 30420713
PMC: 6232142.
DOI: 10.1038/s41598-018-34750-8.
Skeletal Muscle Channelopathies.
Phillips L, Trivedi J
Neurotherapeutics. 2018; 15(4):954-965.
PMID: 30341599
PMC: 6277285.
DOI: 10.1007/s13311-018-00678-0.
Na1.4 DI-S4 periodic paralysis mutation R222W enhances inactivation and promotes leak current to attenuate action potentials and depolarize muscle fibers.
Bayless-Edwards L, Winston V, Lehmann-Horn F, Arinze P, Groome J, Jurkat-Rott K
Sci Rep. 2018; 8(1):10372.
PMID: 29991727
PMC: 6039468.
DOI: 10.1038/s41598-018-28594-5.
Review of the Diagnosis and Treatment of Periodic Paralysis.
Statland J, Fontaine B, Hanna M, Johnson N, Kissel J, Sansone V
Muscle Nerve. 2017; 57(4):522-530.
PMID: 29125635
PMC: 5867231.
DOI: 10.1002/mus.26009.
N1366S mutation of human skeletal muscle sodium channel causes paramyotonia congenita.
Ke Q, Ye J, Tang S, Wang J, Luo B, Ji F
J Physiol. 2017; 595(22):6837-6850.
PMID: 28940424
PMC: 5685822.
DOI: 10.1113/JP274877.
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.
Imbrici P, Liantonio A, Camerino G, De Bellis M, Camerino C, Mele A
Front Pharmacol. 2016; 7:121.
PMID: 27242528
PMC: 4861771.
DOI: 10.3389/fphar.2016.00121.
Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.
Sansone V, Burge J, McDermott M, Smith P, Herr B, Tawil R
Neurology. 2016; 86(15):1408-1416.
PMID: 26865514
PMC: 4831040.
DOI: 10.1212/WNL.0000000000002416.
Physiological and Pathophysiological Insights of Nav1.4 and Nav1.5 Comparison.
Loussouarn G, Sternberg D, Nicole S, Marionneau C, LE Bouffant F, Toumaniantz G
Front Pharmacol. 2016; 6:314.
PMID: 26834636
PMC: 4712308.
DOI: 10.3389/fphar.2015.00314.
Hypokalaemia and dysmorphia, is there a link?.
Burtey S, Sternberg D, Nguyen K, Philip N, Berland Y, Dussol B
NDT Plus. 2015; 2(3):222-4.
PMID: 25983995
PMC: 4421201.
DOI: 10.1093/ndtplus/sfp009.
Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis.
Wu F, Mi W, Cannon S
Neurology. 2013; 80(12):1110-6.
PMID: 23427324
PMC: 3662304.
DOI: 10.1212/WNL.0b013e3182886a0e.
Pathophysiological role of omega pore current in channelopathies.
Jurkat-Rott K, Groome J, Lehmann-Horn F
Front Pharmacol. 2012; 3:112.
PMID: 22701429
PMC: 3372090.
DOI: 10.3389/fphar.2012.00112.
Hypokalemic periodic paralysis; two different genes responsible for similar clinical manifestations.
Kim H, Hwang H, Cheong H, Park H
Korean J Pediatr. 2012; 54(11):473-6.
PMID: 22253645
PMC: 3254894.
DOI: 10.3345/kjp.2011.54.11.473.
Skeletal muscle na channel disorders.
Simkin D, Bendahhou S
Front Pharmacol. 2011; 2:63.
PMID: 22016737
PMC: 3192954.
DOI: 10.3389/fphar.2011.00063.
Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies.
Tricarico D, Conte Camerino D
Front Pharmacol. 2011; 2:8.
PMID: 21687503
PMC: 3108473.
DOI: 10.3389/fphar.2011.00008.
Mechanisms underlying a life-threatening skeletal muscle Na+ channel disorder.
Simkin D, Lena I, Landrieu P, Lion-Francois L, Sternberg D, Fontaine B
J Physiol. 2011; 589(Pt 13):3115-24.
PMID: 21521764
PMC: 3145928.
DOI: 10.1113/jphysiol.2011.207977.
An atypical phenotype of hypokalemic periodic paralysis caused by a mutation in the sodium channel gene SCN4A.
Park Y, Kim J
Korean J Pediatr. 2010; 53(10):909-12.
PMID: 21189962
PMC: 3004505.
DOI: 10.3345/kjp.2010.53.10.909.